Stock Update (NYSE MKT:HEB): Hemispherx BioPharma, Inc Announces First Shipment of Newly Manufactured Rintatolimod for Sale to Early Access Program in Europe


Hemispherx BioPharma, Inc (NYSEMKT:HEB) announced that an order of newly manufactured rintatolimod (Ampligen®) for sale utilizing the Early Access Program (EAP) in Europe has been shipped with receipt confirmed on January 26. In May 2016, the Company executed an amended and restated agreement with Impatients N.V., a Netherlands-based company operating as myTomorrows, for the commencement and management of an Early Access Program (EAP) in all of Europe and Turkey. Ampligen® is the trade name in the United States for rintatolimod.

“This new lot of rintatolimod (Ampligen®) will enable Chronic Fatigue Syndrome (CFS) and Pancreatic Cancer patients in the EU and Turkey, to access rintatolimod under early access regulations,” said Tom Equels, CEO of Hemispherx. “The shipment of new product that has been recently released for use in the initiated EAP is an important tangible step in our effort to make our experimental drug Ampligen® available to individuals with CFS and Pancreatic Cancer.”

Shares of Hemispherx are currently trading at $0.67, down $0.020 or -2.87%. HEB has a 1-year high of $2.64 and a 1-year low of $0.59. The stock’s 50-day moving average is $0.76 and its 200-day moving average is $0.78.

Hemispherx Biopharma, Inc. is a biopharmaceutical company, which engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based disorders. Its products include Alferon N Injection and the experimental immunotherapeutic/antiviral Ampligen. Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. Ampligen includes application as a treatment for Chronic Fatigue Syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments.

 

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts